Jochen M Schmitt1, Daniel E Ford. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. jochen.schmitt@uniklinikum-dresden.de
Abstract
BACKGROUND: According to current guidelines the cost of productivity loss should be considered in pharmacoeconomic analyses. The cost of health-related productivity loss in psoriasis patients is unknown. OBJECTIVE: To estimate the cost of productivity loss in psoriasis and its association with health-related quality of life and clinical disease severity. METHODS: Cross-sectional study, recruitment of adult participants through Internet advertisements. 201 (72.3%) out of 278 eligible participants completed the study. Health-related work productivity loss, quality of life and clinical severity of psoriasis were assessed by standardized instruments. RESULTS: Indirect costs of productivity loss clearly exceed the total direct cost. In contrast to objective clinical disease severity, health-related quality of life (measured by the Dermatology Life Quality Index) is an independent predictor of work productivity. CONCLUSIONS: There is good reason to believe that intervention can reduce health-related productivity loss by improving patients' quality of life. Savings from increased work productivity might offset comparatively high acquisition costs of biological agents. Copyright 2006 S. Karger AG, Basel.
BACKGROUND: According to current guidelines the cost of productivity loss should be considered in pharmacoeconomic analyses. The cost of health-related productivity loss in psoriasispatients is unknown. OBJECTIVE: To estimate the cost of productivity loss in psoriasis and its association with health-related quality of life and clinical disease severity. METHODS: Cross-sectional study, recruitment of adult participants through Internet advertisements. 201 (72.3%) out of 278 eligible participants completed the study. Health-related work productivity loss, quality of life and clinical severity of psoriasis were assessed by standardized instruments. RESULTS: Indirect costs of productivity loss clearly exceed the total direct cost. In contrast to objective clinical disease severity, health-related quality of life (measured by the Dermatology Life Quality Index) is an independent predictor of work productivity. CONCLUSIONS: There is good reason to believe that intervention can reduce health-related productivity loss by improving patients' quality of life. Savings from increased work productivity might offset comparatively high acquisition costs of biological agents. Copyright 2006 S. Karger AG, Basel.
Authors: Malgorzata Romanowska; Louise Reilly; Colin N A Palmer; Mattias C U Gustafsson; John Foerster Journal: PLoS One Date: 2010-03-16 Impact factor: 3.240
Authors: Charles G Helmick; Hyewon Lee-Han; Shawn C Hirsch; Tiffany L Baird; Christopher L Bartlett Journal: Am J Prev Med Date: 2014-04-18 Impact factor: 5.043